The role of information technology in the implementation of pharmacogenetic testing in real clinical practice
Abstract
Pharmacogenetics is one of the major tools of personalized medicine. Currently, there are more than 250 genes which are available for pharmacogenetic (PG) testing. Obviously, clinicians can’t handle all this information and feel self-confident while interpreting PG results. Clinical decision support system (CDSS) is known to help clinicians manage the complexities of genetics at the point of care. This review presents different types of CDSS, their architecture and how they work. Moreover, problems with implementation of PG tests in real clinical practice are discussed in this review.
About the Author
E. A. Kochetova
Russian Medical Academy of Postgraduate Education
Russian Federation
Russian Federation
Department of Clinical Pharmacology and Therapeutics
Moscow
References
1. Huang S.M. Effect of pharmacogenetics and drug-drug interactions on exposure-response: what needs to be done.Proceedings of the 32nd Annual meeting of American College of Clinical Pharmacology, Exposure-Response (E-R) Relationships- From Research to Clinic: Adjusting Dosage Regimens to Manage Risks; 2003 Sep 21; Tampa, FL, USA.
2. Davies E.C., Green C.F., Mottram D.R., Pirmohamed M. Adverse drug reactions in hospitals: a narrative review. Curr. DrugSaf. 2007 Jan;2(1):79-87.
3. Classen D.C., Pestotnik S.L., Evans R.S., Lloyd J.F., Burke J.P. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997;277:301—6.
4. Kirchheiner J., Bertilsson L., Bruus H., Wolff A., Roots I., Bauer M. Individualized Medicine — Implementation of Pharmacogenetic Diagnostics in Antidepressant Drug Treatment of Major Depressive Disorders. Pharmacopsychiatry 2003; 36: 235-243.
5. Ramsey L.B., Johnson S.G., Caudle K.E., Haidar C.E.,Voora D., Wilke R.A. et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update. ClinPharmacolTher. 2014 Oct; 96(4): 423—428.
6. Кукес В.Г., Сычёв Д.А., Игнатьев И.В. Клиническая фармакогенетика и практическое здравоохранение: перспективы интеграции. Биомедицина 2006, №5.
7. McLeod H.L., Krynetski E.Y., Relling M.V., Evans W.E. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 2000;14:567-572.
8. Frueh F.W. Co-Development of Drug and Test — Is It a Special Challenge with PGx? Proceedings of the 18th Annual DIA EuroMeeting, March 8, 2006; Paris, France.
9. Pollack A. Patient’s DNA may be signal to tailor medication. The New York Times. 2008 Dec 29.
10. Герасимова К.В. Организационно-экономические аспекты внедрения фармакогенетического тестирования в практическое здравоохранение [диссертация]. Москва, ПМГМУ им.И.М.Сеченова; 2011.
11. Барышева В.О., Кетова Г.Г., Кремлев С.Л., Климова Е.В. Уровень информированности врачей Челябинской области о фармакогенетике и фармакогенетическом тестировании. Вестник ЮУрГУ. Серия: Образование, здравоохранение, физическая культура; 2013. №3.
12. Bartlett M.J., Green D.W., Shephard E.A. Pharmacogenetic testing in the UK clinical setting. Lancet 2013 Jun 1;381(9881):1903.
13. Walden L.M., Brandl E.J., Changasi A., Sturgess J.E., Soibel A., Notario J.F. Physicians’ opinions following pharmacogenetic testing for psychotropic medication. PsychiatryResearch, Volume 229, Issue 3, 913 — 918.
14. Thompson C., Hamilton S.P., Hippman C. Psychiatrist attitudes towards pharmacogenetic testing, direct-to-consumer genetic testing, and integrating genetic counseling into psychiatric patient care. PsychiatryRes. 2015 Mar 30;226(1):68-72.
15. Lærum H., Bremer S., Bergan S., Grünfeld T. A taste of individualized medicine: physicians’ reactions to automated genetic interpretations. J AmMedInformAssoc. 2014 Feb;21(e1):e143-e146.
16. Vitek C.R., Nicholson W.T., Schultz C., Caraballo P.J. Evaluation of the use of clinical decision support and online resources for pharmacogenomics education. Pharmacogenomics 2015;16(14):1595-603.
17. Berner E.S. Clinical decision support systems: State of the Art. Agency for Healthcare Research and Quality 2009 June; Publication No. 09-0069-EF.
18. Overby C.L., Tarczy-Hornoch P.,Kalet I.J., Thummel K.E., Smith J.W. et al. Developing a Prototype System for Integrating Pharmacogenomics Findings into Clinical Practice. J Pers Med. 2012 Dec; 2(4): 241—256.
19. Bell G.C., Crews K.R., Wilkinson M.R., Haidar C.E., Hicks J.K., Baker D.K. et al. Development and use of active clinical decision support for preemptive pharmacogenomics. J Am Med Inform Assoc. 2014 Feb;21(e1):e93-9.
20. Welch B.M, Kawamoto K. The Need for Clinical Decision Support Integrated with the Electronic Health Record for the Clinical Application of Whole Genome Sequencing Information. J Pers Med. 2013 Dec; 3(4): 306—325.
21. Watt S., Jiao W., Brown A.M., Petrocelli T., Tran B., Zhang T. et al. Clinical genomics information management software linking cancer genome sequence and clinical decisions. Genomics. 2013 Sep;102(3):140-7.
22. Peterson J.F., Bowton E., Field J.R., Beller M., Mitchell J., Schildcrout J. et al. Electronic Health Record Design and Implementation for Pharmacogenomics: a Local Perspective. Genet Med. 2013 Oct; 15(10): 833—841.
23. Rodríguez-González A., Torres-Niño J., Mayer M.A., Alor-Hernandez G., Wilkinson M.D. Analysis of a multilevel diagnosis decision support system and its implications: a case study. ComputMathMethodsMed. 2012;2012:367345.
24. Weitzel K.W., Elsey A.R., Langaee T.Y., Burkley B., Nessl D.R., Obeng A.O. et al. Clinical pharmacogenetics implementation: Approaches, successes, and challenges. Am J Med Genet Part C Semin Med Genet 2014;9999:1—12.
25. Hoffman J.M., Haidar C.E., Wilkinson M.R., Crews K.R., Baker D.K., Kornegay N.M. et al. PG4KDS: a model for the clinical implementation of preemptive pharmacogenetics. Am J Med Genet C Semin Med Genet. 2014 Mar;166C(1):45-55.
26. O’Donnell P.O., Bush A., Spitz J., Danahey K., Saner D., Das S. et al. The 1200 Patients Project: Creating A New Medical Model System for Clinical Implementation of Pharmacogenomics. ClinPharmacolTher. 2012 Oct; 92(4): 446—449.
27. O’Donnell P.H., Danahey K., Jacobs M., Wadhwa N.R., Yuen S., Bush A. et al. Adoption of a clinical pharmacogenomics implementation program during outpatient care--initial results of the University of Chicago «1,200 Patients Project». Am J Med Genet C Semin Med Genet. 2014 Mar;166C(1):68-75.
28. Minarro-Gime´nez J.A., Blagec K., Boyce R.D., Adlassnig K-P., Samwald M. An Ontology-Based, Mobile-Optimized System for Pharmacogenomic Decision Support at the Point-of-Care. PLoS ONE 9(5): e93769.
29. Blagec K., Romagnoli K.M., Boyce R.D., Samwald M. Examining perceptions of the usefulness and usability of a mobile-based system for pharmacogenomics clinical decision support: a mixed methods study. PeerJ. 2016;4:e1671.
30. Цветов В.М., Сычёв Д.А., Игнатьев И.В., Антонов И.М., Кетова Г.Г. Первый опыт информатизации фармакогенетического тестирования для прогнозирования дозирования варфарина. Биомедицина 2011, №4.
31. Сычёв Д.А., Антонов И.М., Кропачева Е.С., Панченко Е.П. Какой из алгоритмов дозирования варфарина, основанных на результатах фармакогенетического тестирования, подходит российским пациентам? Кардиология 2010, №4.
Review
For citations:
Kochetova E.A. The role of information technology in the implementation of pharmacogenetic testing in real clinical practice. Pharmacogenetics and Pharmacogenomics. 2016;(1):29-34. (In Russ.)
Views:
494
Email this article 
Post a Comment 